title: Hypomagnesaemia in critically ill patients with haematological malignancies.
abstract: BACKGROUND
  There is currently little information regarding the incidence of hypomagnesaemia and its impact on the prognosis of critically ill patients with haematological malignancies.
  
  
  OBJECTIVE
  This study sought to describe the incidence of hypomagnesaemia in critically ill patients with haematological malignancies admitted to an oncological intensive care unit (ICU).
  
  
  METHODS
  A total of 102 critically ill patients with haematological malignancies, who were 18 years of age and admitted to the ICU between January 2008 and April 2011, were included in this study. Hypomagnesaemia was defined as a serum magnesium concentration below 1.7 mg/dl.
  
  
  RESULTS
  The incidence of hypomagnesaemia at admission or during the first 24 hours of stay in the ICU was 22.5% (23/102). The hospital mortality rates of patients with and without hypomagnesaemia were 47.8% and 60.7%, respectively.
  
  
  CONCLUSIONS
  The incidence of hypomagnesaemia in critically ill patients with haematological malignancies was 22.5%. Mortality in the ICU and in the hospital was similar in patients with and without hypomagnesaemia.
authors.affiliation: Head, Department of Critical Care Medicine. Instituto Nacional de Cancerología. Mexico City. Mexico. Department of Critical Care Medicine. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Mexico City. Mexico.. snamendys@incan.edu.mx.
authors.forename: Silvio A
authors.initials: SA
authors.lastname: Namendys-Silva
authors.affiliation: Department of Critical Care Medicine. Instituto Nacional de Cancerología. Mexico City. Mexico..
authors.forename: Paulina
authors.initials: P
authors.lastname: Correa-García
authors.affiliation: Department of Critical Care Medicine. Instituto Nacional de Cancerología. Mexico City. Mexico..
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: García-Guillén
authors.affiliation: Department of Critical Care Medicine. Instituto Nacional de Cancerología. Mexico City. Mexico..
authors.forename: Julia
authors.initials: J
authors.lastname: Texcocano-Becerra
authors.affiliation: Department of Critical Care Medicine. Instituto Nacional de Cancerología. Mexico City. Mexico..
authors.forename: Gisela
authors.initials: G
authors.lastname: Colorado-Castillo
authors.affiliation: Director. Instituto Nacional de Cancerología. Mexico City. Mexico..
authors.forename: Abelardo
authors.initials: A
authors.lastname: Meneses-García
authors.affiliation: Medical Director. Instituto Nacional de Cancerología. Mexico City. Mexico..
authors.forename: Angel
authors.initials: A
authors.lastname: Herrera-Gómez
mesh_terms: D000328:Adult; D016638:Critical Illness; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000401:mortality; D017052:Hospital Mortality; D006801:Humans; D015994:Incidence; D008274:Magnesium / Q000378:metabolism*; D008297:Male; D008659:Metabolic Diseases / Q000453:epidemiology / Q000209:etiology*; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D008274:Magnesium